Recurrent Gallbladder Carcinoma

7 clinical trials · Condition

Record	Firm	Date
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer (NCT04941287)	National Cancer Institute (NCI)	2021-12-15
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer (NCT03257761)	University of Southern California	2018-02-07
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02495896)	University of Southern California	2015-09-03
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (NCT02042443)	National Cancer Institute (NCI)	2014-02-01
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery (NCT01425879)	National Cancer Institute (NCI)	2011-04-01
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma (NCT01093222)	National Cancer Institute (NCI)	2010-04-01

Every clearance here is in the API, with alerts when new ones post.